A Trial to Evaluate the Combination of Iressa & FaslodexÂ® in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer
Breast Cancer
DRUG: gefitinib and fulvestrant
To evaluate the progression-free survival (PFS) of the combination of 250 mg ZD1839 and fulvestrant in patients with advanced or metastatic breast cancer
To estimate the objective response rate (complete response [CR] and partial response [PR]) at trial closure.|To estimate the disease control rate at trial closure.|To estimate overall survival.|To evaluate the safety & tolerability of the combination gefitinib and fulvestrant
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer